Paratek Pharmaceuticals PE Ratio 2006-2021 | PRTK

Current and historical p/e ratio for Paratek Pharmaceuticals (PRTK) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Paratek Pharmaceuticals PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Paratek Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 5.00 0.00
2021-06-30 6.82 $-1.19 0.00
2021-03-31 7.06 $-1.92 0.00
2020-12-31 6.26 $-2.19 0.00
2020-09-30 5.41 $-2.46 0.00
2020-06-30 5.22 $-3.00 0.00
2020-03-31 3.15 $-3.49 0.00
2019-12-31 4.03 $-3.93 0.00
2019-09-30 4.32 $-3.83 0.00
2019-06-30 3.99 $-3.84 0.00
2019-03-31 5.36 $-3.76 0.00
2018-12-31 5.13 $-3.57 0.00
2018-09-30 9.70 $-3.64 0.00
2018-06-30 10.20 $-3.40 0.00
2018-03-31 13.00 $-3.12 0.00
2017-12-31 17.90 $-3.35 0.00
2017-09-30 25.10 $-3.73 0.00
2017-06-30 24.10 $-4.00 0.00
2017-03-31 19.25 $-5.03 0.00
2016-12-31 15.40 $-5.67 0.00
2016-09-30 13.01 $-5.71 0.00
2016-06-30 13.91 $-6.00 0.00
2016-03-31 15.17 $-5.27 0.00
2015-12-31 18.97 $-4.23 0.00
2015-09-30 19.00 $-4.19 0.00
2015-06-30 25.77 $-358.04 0.00
2015-03-31 31.26 $-398.87 0.00
2014-12-31 38.55 $-399.93 0.00
2014-09-30 23.33 $-402.25 0.00
2014-06-30 22.92 $-50.07 0.00
2014-03-31 21.56 $-12.61 0.00
2013-12-31 23.52 $-17.53 0.00
2013-09-30 22.26 $-18.25 0.00
2013-06-30 21.14 $-12.24 0.00
2013-03-31 33.53 $-11.52 0.00
2012-12-31 31.15 $-9.24 0.00
2012-09-30 37.17 $-0.60 0.00
2012-06-30 43.40 $-8.04 0.00
2012-03-31 73.64 $-6.48 0.00
2011-12-31 54.81 $-3.72 0.00
2011-09-30 46.34 $-10.56 0.00
2011-06-30 76.65 $-8.64 0.00
2011-03-31 57.33 $-8.40 0.00
2010-12-31 51.80 $-8.40 0.00
2010-09-30 48.79 $-8.16 0.00
2010-06-30 58.31 $-9.12 0.00
2010-03-31 55.79 $-13.81 0.00
2009-12-31 47.60 $-23.53 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.237B $0.047B
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86